Evotec and Yale University form Open Innovation Alliance

Published: 21-Jan-2013

Will jointly assess and potentially pursue novel assays, screens and models


German small molecule drug developer Evotec has joined forces with Yale University in the US in which the biology performed at Yale will be combined with Evotec’s drug discovery infrastructure to develop innovative discovery approaches to diseases of high unmet medical need. Initially, Evotec and Yale have defined a range of scientific fields including metabolic diseases, CNS, immunological diseases and cancer where they will jointly assess and potentially pursue novel assays, screens and models but in particular exploratory drug targets and compounds.

Dr Cord Dohrmann, chief scientific officer of Evotec, said: ‘There is a tremendous wealth of scientific innovation at Yale that has the potential to be directly translated into first- and best-in-class drug candidates. Together we want significantly to accelerate this process by removing technical bottlenecks and focusing all efforts on bringing individual projects to highest industrial standards in preparation for development and commercialisation partnerships with pharma companies.’

Dr Jon Soderstrom, MD of Yale’s Office of Cooperative Research, added: ‘This agreement is a new collaboration model between academia and the pharmaceutical industry. It essentially gives all faculties at Yale the opportunity to directly translate new biological insights into top-notch drug discovery projects.’

No financial details were disclosed.

You may also like